CAS 177036-94-1 Purity >99.0% (HPLC) API Factory High Purity

Short Description:

CAS: 177036-94-1

Purity: >99.0% (HPLC)

Appearance: White or Off-White Powder

Treatment of Pulmonary Arterial Hypertension (PAH)

API High Quality, Commercial Production

E-Mail: alvin@ruifuchem.com


Product Detail

Related Products

Product Tags

Description:

Chemical Properties:

Chemical Name (S)-2-[(4,6-Dimethylpyrimidin-2-yl)oxy]-3-Methoxy-3,3-Diphenylpropionic Acid
Synonyms (+-)-(2S)-2-((4,6-Dimethylpyrimidin-2-yl)oxy)-3-Methoxy-3,3-Diphenylpropanoic Acid
CAS Number 177036-94-1
Stock Status In Stock, Production Scale Up to Tons
Molecular Formula C22H22N2O4
Molecular Weight 378.43
Specific Rotation [α]D20 +170.0° to +176.0° (C=0.5, MeOH)
Melting Point 172.0~178.0℃(dec.)
Solubility Very Soluble in Methanol; Soluble in Ethanol, Acetone; Insoluble in Water
Brand Ruifu Chemical

Specifications:

Item Specifications
Appearance White or Off-White Powder
Identification HPLC;  NMR; LC-MS
Related Substances  
Individual Impurity ≤0.50%
Total Impurities <1.00%
Loss on Drying ≤0.50%
Residue on Ignition ≤0.20%
Heavy Metals ≤20ppm
Purity / Analysis Method >99.0% (HPLC)
Test Standard Enterprise Standard
Usage Pharmaceutical Intermediates

Package & Storage:

Package: Bottle, Aluminium foil bag, 25kg/Cardboard Drum, or according to customer's requirement

Storage Condition: Store in sealed containers at cool and dry place; Protect from light and moisture

Advantages:

1

FAQ:

Application:

(CAS: 177036-94-1) API is a selective endothelin-A (ETA) receptor antagonist introduced for the oral treatment of patients with pulmonary arterial hypertension (PAH), to improve exercise capacity and delay clinical worsening. PAH is a rare disease of the small pulmonary arteries characterized by vascular proliferation and remodeling, resulting in a progressive increase in pulmonary vascular resistance and pulmonary arterial pressure, and ultimately, right ventricular failure and premature death. Early symptoms of PAH include gradual onset of shortness of breath, fatigue, palpitation, edema, and fainting. Endothelin-1 (ET-1), a potent vasoconstrictor and smooth muscle mitogen, is a key contributor to the acceleration of the disease, and its effects are mediated through activation ofETA and ETB receptors. In June of 2007, the FDA granted approvalof (CAS: 177036-94-1) API for once-daily treatment of PAH. 

  • Write your message here and send it to us